Psychostimulant addiction treatment
Treatment of psychostimulant addiction has been a major, and not fully met, challenge. For opioid addiction, there is strong evidence for the effectiveness of several medications. For psychostimulants, there is no corresponding form of agonist maintenance that has met criteria for regulatory approva...
Gespeichert in:
Veröffentlicht in: | Neuropharmacology 2014-12, Vol.87, p.150-160 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 160 |
---|---|
container_issue | |
container_start_page | 150 |
container_title | Neuropharmacology |
container_volume | 87 |
creator | Phillips, Karran A. Epstein, David H. Preston, Kenzie L. |
description | Treatment of psychostimulant addiction has been a major, and not fully met, challenge. For opioid addiction, there is strong evidence for the effectiveness of several medications. For psychostimulants, there is no corresponding form of agonist maintenance that has met criteria for regulatory approval or generally accepted use. Stimulant-use disorders remain prevalent and can result in both short-term and long-term adverse consequences. The mainstay of treatment remains behavioral interventions. In this paper, we discuss those interventions and some promising candidates in the search for pharmacological interventions.
This article is part of the Special Issue entitled ‘CNS Stimulants’.
•Stimulant-use disorders remain prevalent.•Stimulant-use disorders can result in both short- and long-term adverse consequences.•No pharmacological intervention with regulatory approval or generally accepted use.•The mainstay of treatment remains behavioral interventions. |
doi_str_mv | 10.1016/j.neuropharm.2014.04.002 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4524548</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0028390814001282</els_id><sourcerecordid>24727297</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-e0cd0ac58de419b4fa0abfd2c07e9d8783e7bec2030822931c4dea55a36618333</originalsourceid><addsrcrecordid>eNqFkEtLAzEQx4Motla_ghQ87zp57CZ7EbT4goIe9ByyydSmdHdLNi3025tSrXoSBgZm_g_4ETKmkFOg5fUib3EdutXchCZnQEUOaYAdkSFVkmcSSnFMhumiMl6BGpCzvl8AgFBUnZIBE5JJVskhuXrtt3be9dE366Vp49g45230XTuOAU1ssI3n5GRmlj1efO0ReX-4f5s8ZdOXx-fJ7TSzhahihmAdGFsoh4JWtZgZMPXMMQsSK6ek4ihrtAw4KMYqTq1waIrC8LKkinM-Ijf73NW6btDZVB3MUq-Cb0zY6s54_ffT-rn-6DZaFEwUQqUAtQ-woev7gLODl4LegdML_QNO78BpSAMsWS9_dx-M36SS4G4vwERg4zHo3npsLTof0EbtOv9_yydCxYZf</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Psychostimulant addiction treatment</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Phillips, Karran A. ; Epstein, David H. ; Preston, Kenzie L.</creator><creatorcontrib>Phillips, Karran A. ; Epstein, David H. ; Preston, Kenzie L.</creatorcontrib><description>Treatment of psychostimulant addiction has been a major, and not fully met, challenge. For opioid addiction, there is strong evidence for the effectiveness of several medications. For psychostimulants, there is no corresponding form of agonist maintenance that has met criteria for regulatory approval or generally accepted use. Stimulant-use disorders remain prevalent and can result in both short-term and long-term adverse consequences. The mainstay of treatment remains behavioral interventions. In this paper, we discuss those interventions and some promising candidates in the search for pharmacological interventions.
This article is part of the Special Issue entitled ‘CNS Stimulants’.
•Stimulant-use disorders remain prevalent.•Stimulant-use disorders can result in both short- and long-term adverse consequences.•No pharmacological intervention with regulatory approval or generally accepted use.•The mainstay of treatment remains behavioral interventions.</description><identifier>ISSN: 0028-3908</identifier><identifier>EISSN: 1873-7064</identifier><identifier>DOI: 10.1016/j.neuropharm.2014.04.002</identifier><identifier>PMID: 24727297</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Addiction ; Central Nervous System Stimulants - administration & dosage ; Central Nervous System Stimulants - pharmacokinetics ; Humans ; Psychostimulant ; Randomized Controlled Trials as Topic ; Self Administration ; Substance Withdrawal Syndrome - physiopathology ; Substance Withdrawal Syndrome - therapy ; Substance-Related Disorders - physiopathology ; Substance-Related Disorders - therapy ; Treatment</subject><ispartof>Neuropharmacology, 2014-12, Vol.87, p.150-160</ispartof><rights>2014</rights><rights>Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c549t-e0cd0ac58de419b4fa0abfd2c07e9d8783e7bec2030822931c4dea55a36618333</citedby><cites>FETCH-LOGICAL-c549t-e0cd0ac58de419b4fa0abfd2c07e9d8783e7bec2030822931c4dea55a36618333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0028390814001282$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24727297$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Phillips, Karran A.</creatorcontrib><creatorcontrib>Epstein, David H.</creatorcontrib><creatorcontrib>Preston, Kenzie L.</creatorcontrib><title>Psychostimulant addiction treatment</title><title>Neuropharmacology</title><addtitle>Neuropharmacology</addtitle><description>Treatment of psychostimulant addiction has been a major, and not fully met, challenge. For opioid addiction, there is strong evidence for the effectiveness of several medications. For psychostimulants, there is no corresponding form of agonist maintenance that has met criteria for regulatory approval or generally accepted use. Stimulant-use disorders remain prevalent and can result in both short-term and long-term adverse consequences. The mainstay of treatment remains behavioral interventions. In this paper, we discuss those interventions and some promising candidates in the search for pharmacological interventions.
This article is part of the Special Issue entitled ‘CNS Stimulants’.
•Stimulant-use disorders remain prevalent.•Stimulant-use disorders can result in both short- and long-term adverse consequences.•No pharmacological intervention with regulatory approval or generally accepted use.•The mainstay of treatment remains behavioral interventions.</description><subject>Addiction</subject><subject>Central Nervous System Stimulants - administration & dosage</subject><subject>Central Nervous System Stimulants - pharmacokinetics</subject><subject>Humans</subject><subject>Psychostimulant</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Self Administration</subject><subject>Substance Withdrawal Syndrome - physiopathology</subject><subject>Substance Withdrawal Syndrome - therapy</subject><subject>Substance-Related Disorders - physiopathology</subject><subject>Substance-Related Disorders - therapy</subject><subject>Treatment</subject><issn>0028-3908</issn><issn>1873-7064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLAzEQx4Motla_ghQ87zp57CZ7EbT4goIe9ByyydSmdHdLNi3025tSrXoSBgZm_g_4ETKmkFOg5fUib3EdutXchCZnQEUOaYAdkSFVkmcSSnFMhumiMl6BGpCzvl8AgFBUnZIBE5JJVskhuXrtt3be9dE366Vp49g45230XTuOAU1ssI3n5GRmlj1efO0ReX-4f5s8ZdOXx-fJ7TSzhahihmAdGFsoh4JWtZgZMPXMMQsSK6ek4ihrtAw4KMYqTq1waIrC8LKkinM-Ijf73NW6btDZVB3MUq-Cb0zY6s54_ffT-rn-6DZaFEwUQqUAtQ-woev7gLODl4LegdML_QNO78BpSAMsWS9_dx-M36SS4G4vwERg4zHo3npsLTof0EbtOv9_yydCxYZf</recordid><startdate>20141201</startdate><enddate>20141201</enddate><creator>Phillips, Karran A.</creator><creator>Epstein, David H.</creator><creator>Preston, Kenzie L.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20141201</creationdate><title>Psychostimulant addiction treatment</title><author>Phillips, Karran A. ; Epstein, David H. ; Preston, Kenzie L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-e0cd0ac58de419b4fa0abfd2c07e9d8783e7bec2030822931c4dea55a36618333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Addiction</topic><topic>Central Nervous System Stimulants - administration & dosage</topic><topic>Central Nervous System Stimulants - pharmacokinetics</topic><topic>Humans</topic><topic>Psychostimulant</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Self Administration</topic><topic>Substance Withdrawal Syndrome - physiopathology</topic><topic>Substance Withdrawal Syndrome - therapy</topic><topic>Substance-Related Disorders - physiopathology</topic><topic>Substance-Related Disorders - therapy</topic><topic>Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Phillips, Karran A.</creatorcontrib><creatorcontrib>Epstein, David H.</creatorcontrib><creatorcontrib>Preston, Kenzie L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Phillips, Karran A.</au><au>Epstein, David H.</au><au>Preston, Kenzie L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psychostimulant addiction treatment</atitle><jtitle>Neuropharmacology</jtitle><addtitle>Neuropharmacology</addtitle><date>2014-12-01</date><risdate>2014</risdate><volume>87</volume><spage>150</spage><epage>160</epage><pages>150-160</pages><issn>0028-3908</issn><eissn>1873-7064</eissn><abstract>Treatment of psychostimulant addiction has been a major, and not fully met, challenge. For opioid addiction, there is strong evidence for the effectiveness of several medications. For psychostimulants, there is no corresponding form of agonist maintenance that has met criteria for regulatory approval or generally accepted use. Stimulant-use disorders remain prevalent and can result in both short-term and long-term adverse consequences. The mainstay of treatment remains behavioral interventions. In this paper, we discuss those interventions and some promising candidates in the search for pharmacological interventions.
This article is part of the Special Issue entitled ‘CNS Stimulants’.
•Stimulant-use disorders remain prevalent.•Stimulant-use disorders can result in both short- and long-term adverse consequences.•No pharmacological intervention with regulatory approval or generally accepted use.•The mainstay of treatment remains behavioral interventions.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>24727297</pmid><doi>10.1016/j.neuropharm.2014.04.002</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0028-3908 |
ispartof | Neuropharmacology, 2014-12, Vol.87, p.150-160 |
issn | 0028-3908 1873-7064 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4524548 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Addiction Central Nervous System Stimulants - administration & dosage Central Nervous System Stimulants - pharmacokinetics Humans Psychostimulant Randomized Controlled Trials as Topic Self Administration Substance Withdrawal Syndrome - physiopathology Substance Withdrawal Syndrome - therapy Substance-Related Disorders - physiopathology Substance-Related Disorders - therapy Treatment |
title | Psychostimulant addiction treatment |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T17%3A53%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psychostimulant%20addiction%20treatment&rft.jtitle=Neuropharmacology&rft.au=Phillips,%20Karran%20A.&rft.date=2014-12-01&rft.volume=87&rft.spage=150&rft.epage=160&rft.pages=150-160&rft.issn=0028-3908&rft.eissn=1873-7064&rft_id=info:doi/10.1016/j.neuropharm.2014.04.002&rft_dat=%3Cpubmed_cross%3E24727297%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/24727297&rft_els_id=S0028390814001282&rfr_iscdi=true |